Documentation of study medication dispensing in a prospective large randomized clinical trial: Experiences from the ARISTOTLE Trial - 07/09/13
, Elliott Levy, MD b, Jack Lawrence, MD b, Michael Hanna, MD b, Anthony P. Waclawski, MS, PhD b, Junyuan Wang, PhD b, Robert M. Califf, MD c, Lars Wallentin, MD, PhD d, Christopher B. Granger, MD aRésumé |
Background |
In ARISTOTLE, apixaban resulted in a 21% reduction in stroke, a 31% reduction in major bleeding, and an 11% reduction in death. However, approval of apixaban was delayed to investigate a statement in the clinical study report that “7.3% of subjects in the apixaban group and 1.2% of subjects in the warfarin group received, at some point during the study, a container of the wrong type.”
Methods |
Rates of study medication dispensing error were characterized through reviews of study medication container tear-off labels in 6,520 participants from randomly selected study sites. The potential effect of dispensing errors on study outcomes was statistically simulated in sensitivity analyses in the overall population.
Results |
The rate of medication dispensing error resulting in treatment error was 0.04%. Rates of participants receiving at least 1 incorrect container were 1.04% (34/3,273) in the apixaban group and 0.77% (25/3,247) in the warfarin group. Most of the originally reported errors were data entry errors in which the correct medication container was dispensed but the wrong container number was entered into the case report form. Sensitivity simulations in the overall trial population showed no meaningful effect of medication dispensing error on the main efficacy and safety outcomes.
Conclusions |
Rates of medication dispensing error were low and balanced between treatment groups. The initially reported dispensing error rate was the result of data recording and data management errors and not true medication dispensing errors. These analyses confirm the previously reported results of ARISTOTLE.
Le texte complet de cet article est disponible en PDF.Plan
| NCT00412984. |
Vol 166 - N° 3
P. 559 - septembre 2013 Retour au numéro
Article précédent
- Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
- David A. Garcia, Lars Wallentin, Renato D. Lopes, Laine Thomas, John H. Alexander, Elaine M. Hylek, Jack Ansell, Michael Hanna, Fernando Lanas, Greg Flaker, Patrick Commerford, Denis Xavier, Dragos Vinereanu, Hongqiu Yang, Christopher B. Granger
- African American race but not genome-wide ancestry is negatively associated with atrial fibrillation among postmenopausal women in the Women's Health Initiative
- Marco V. Perez, Thomas J. Hoffmann, Hua Tang, Timothy Thornton, Marcia L. Stefanick, Joseph C. Larson, Charles Kooperberg, Alex P. Reiner, Bette Caan, Carlos Iribarren, Neil Risch
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?